RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc. (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the ...
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering.
BioAge Labs filed confidentially on May 31, 2024. Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
The company's lead drug Azelaprag has been well-tolerated in 265 individuals across eight Phase 1 trials. The STRIDES clinical trial will assess azelaprag with Eli Lilly's Zepbound, with topline ...
Some results have been hidden because they may be inaccessible to you